Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Genomics in Michigan Impacting Observation or Radiation
NCT02783950 · View on ClinicalTrials.gov ↗
Study Summary
To determine the impact of Decipher test results on adjuvant treatment decisions of high-risk post-RP patients with undetectable post-op prostate specific antigen (PSA) compared to clinical factors alone.
Conditions Studied
Interventions
- OTHER Decipher Prostate Cancer Classifier
Study Locations (13)
Michigan
- University of Michigan Hospital and Health Systems — Ann Arbor
- Wayne State University/Karmanos Cancer Institute — Detroit
- Henry Ford Hospital — Detroit
- Urologic Consultants — Grand Rapids
- Urology Associates of Grand Rapids — Grand Rapids
- Michigan Urological Clinic — Grand Rapids
- Spectrum Health Medical Group- Urology — Grand Rapids
- Urology Surgeons, PC — Grand Rapids
- Comprehensive Medical Center, PLLC — Royal Oak
- Tri-City Urology — Saginaw
- Bay Area Urology Associates, PC — Traverse City
- Michigan Institute of Urology-Town Center — Troy
- IHA Urology at St. Joe's Ann Arbor — Ypsilanti
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 356 participants |
| Start Date | 2017-01-17 |
| Est. Completion | 2024-04-02 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02783950
The ClinicalTrials.gov registry entry for NCT02783950 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 356 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 261 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention — of which Decipher Prostate Cancer Classifier is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02783950 reports 13 study locations spanning 1 distinct geographic area — top geographies include Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02783950 about?
NCT02783950 is a clinical study titled "Genomics in Michigan Impacting Observation or Radiation". To determine the impact of Decipher test results on adjuvant treatment decisions of high-risk post-RP patients with undetectable post-op prostate specific antigen (PSA) compared to clinical factors alone.
What is the current status of trial NCT02783950?
This trial is currently completed. It is a NA study. The enrollment target is 356 participants. The study started on 2017-01-17. Estimated completion is 2024-04-02.
What conditions does trial NCT02783950 study?
This clinical trial studies the following conditions: Prostate Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02783950?
The interventions under investigation include: Decipher Prostate Cancer Classifier (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02783950?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 261 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02783950 being conducted?
This trial has 13 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.